Genomic profiles specific to patient ethnicity in lung adenocarcinoma

Clinical Cancer Research

Volumn 17, Issue 11, 2011, Pages 3542-3550

  Broët, Philippe ^a,e,f   Dalmasso, Cyril ^a   Tan, Eng Huat ^b   Alifano, Marco ^f   Zhang, Shenli ^c   Wu, Jeanie ^b   Lee, Ming Hui ^b   Régnard, Jean François ^f,g   Lim, Darren ^b   Koong, Heng Nung ^b   Agasthian, Thirugnanam ^b   Miller, Lance D ^a,h   Lim, Elaine ^c   Camilleri Broët, Sophie ^e   Tan, Patrick ^a,b,d  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; ASIAN; CAUCASIAN; CHROMOSOME 16P; CHROMOSOME 19P; CHROMOSOME ABERRATION; COPY NUMBER ABERRATION; EGFR GENE; ETHNICITY; FEMALE; GENE LOSS; GENE MUTATION; GENETIC GAIN; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; SMOKING; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 19; DNA COPY NUMBER VARIATIONS; EUROPE; FAR EAST; FEMALE; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS;

EID: 79957905683     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2185     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009;59:225-49.
2. Barnes DJ. The changing face of lung cancer. Chest 2004;126:1718-21. (Pubitemid 39643966)
3. Bell DW, Brannigan BW, Matsuo K, Finkelstein DM, Sordella R, Settleman J, et al. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clin Cancer Res 2008;14:4079-84.
4. Toh CK, Wong EH, Lim WT, Leong SS, Fong KW, Wee J, et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest 2004;126:1750-6. (Pubitemid 39643975)
5. Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006;24:2245-51. (Pubitemid 46630653)
6. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005;97:643-55. (Pubitemid 40812628)
7. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-45.
8. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer. Oncogene 2002;21:6877-83. (Pubitemid 35221934)
9. Garnis C, Lockwood WW, Vucic E, Ge Y, Girard L, Minna JD, et al. High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 2006;118:1556-64.
10. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, et al. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 2005;102:9625-30. (Pubitemid 40981731)
11. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-89.
12. Broët P, Camilleri-Broët S, Zhang S, Alifano M, Bangarusamy D, Battistella M, et al. Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. Cancer Res 2009;69:1055-62.
13. Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, et al. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol 2009;4:12-21.
14. Broët P, Richardson S. Detection of gene copy number changes in CGH microarrays using a spatially correlated mixture model. Bioinformatics 2006;22:911-8.
15. Broët P, Tan P, Alifano M, Camilleri-Broët S, Richardson S. Finding exclusively deleted or amplified genomic areas in lung adenocarcinomas using a novel chromosomal pattern analysis. BMC Med Genomics 2009;14:43.
16. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat 2001;29:1165-88. (Pubitemid 33575263)
17. Yee TW, Wild CJ. Vector generalized additive models. J R Stat Soc Ser B 1996;58:481-93.
18. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
19. Sasaki H, Endo K, Takada M, Kawahara M, Kitahara N, Tanaka H, et al. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. Lung Cancer 2006;54:103-8.
20. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005;11:1167-73. (Pubitemid 40175767)
21. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007;7:778-90. (Pubitemid 47463669)
22. Dacic S, Shuai Y, Yousem S, Ohori P, Nikiforova M. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 2010;23:159-68.
23. Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 2009;28:2773-83.
24. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
25. Shah U, Sharpless NE, Hayes DN. LKB1 and lung cancer: more than the usual suspects. Cancer Res 2008;68:3562-5.
26. Shibata T, Uryu S, Kokubu A, Hosoda F, Ohki M, Sakiyama T, et al. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin Cancer Res 2005;11:6177-85. (Pubitemid 41262945)
27. Wang X, Sun SY. Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets 2009;13:1193-203.
28. Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, et al. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer 2008;99:245-52.
29. Wong MP, Fung LF, Wang E, Chow WS, Chiu SW, Lam WK, et al. Chromosomal aberrations of primary lung adenocarcinomas in non-smokers. Cancer 2003;97:1263-70. (Pubitemid 36237313)
30. Alhopuro P, Phichith D, Tuupanen S, Sammalkorpi H, Nybondas M, Saharinen J, et al. Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci U S A 2008;105:5513-8. (Pubitemid 351753894)
31. Ledford H. Big science: the cancer genome challenge. Nature 2010;464:972-4.